Table 4. Serious adverse events in the early postoperative period.
| Groups# | TAVI | SAVR | |||||
|---|---|---|---|---|---|---|---|
| 2018 (n=25) | 2019 (n=25) | 2020 (n=37) | 2018 (n=25) | 2019 (n=27) | 2020 (n=19) | ||
| Myocardial infarct | – | – | 1 (2.7) | 2 (8.0) | 1 (3.7) | – | |
| Complete AVB | 5 (20.0) | 6 (24.0) | 5 (13.5) | 1 (4.0) | 2 (7.4) | 2 (10.5) | |
| Renal failure | 1 (4.0) | 2 (8.0) | 2 (5.4) | 1 (4.0) | – | 3 (15.8) | |
| Respiratory failure | 1 (4.0) | 1 (4.0) | 1 (2.7) | 1 (4.0) | – | 2 (10.5) | |
| Stroke | – | – | 1 (2.7) | – | – | – | |
| Bleeding/tamponade | 1 (4.0) | 1 (4.0) | – | 1 (4.0) | 2 (7.4) | 1 (5.3) | |
| DSSI | N/A | N/A | N/A | – | 1 (3.7) | – | |
| Peripheral access adverse event | 1 (4.0) | 1 (4.0) | 1 (2.7) | N/A | N/A | N/A | |
#, All data are presented as the numbers (n) with percentage (%), definition of all serious adverse events are listed in the text (‘method’). TAVI, transcatheter aortic valve implantation; SAVR, surgical aortic valve replacement; AVB, atrioventricular block; DSSI, deep surgical site infection; N/A, non-applicable.